The Week Ahead: Hom...
Health Care: Drugs
Celgene Corporation (CELG: NASDAQ)
$124.91 1.43 | 1.16%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 1.46B | 1.32B | 880.19M | 776.75M |
| Operating Gains/Losses | 21.84M | 36.37M | 52.04M | 17.06M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -30.05M | -263.13M | -234.45M | -122.62M |
| (Increase) Decrease in Inventories | -69.68M | 70.98M | 18.72M | 1.54M |
| (Increase) Decrease In Other Current Assets | -1.18M | 2.36M | 3.00M | 0.00 |
| (Decrease) Increase In Payables | 68.19M | 223.81M | 51.56M | 652.00K |
| (Decrease) Increase In Other Current Liabilities | -455.48M | 95.33M | 78.11M | 39.82M |
| (Increase) Decrease In Other Working Capital | 98.37M | -94.55M | -24.79M | -50.06M |
| Other Non-Cash Items | 546.72M | 143.03M | 202.01M | 147.57M |
| Net Cash From Continuing Operations | 2.02B | 1.81B | 1.18B | 909.86M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 2.02B | 1.81B | 1.18B | 909.86M |
| Sale of Property, Plant & Equipment | 15.78M | 93.18M | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 1.74B | 2.18B | 3.93B | 2.26B |
| Purchases of Property, Plant & Equipment | -160.39M | -132.12M | -98.63M | -93.38M |
| Acquisitions | -352.24M | 0.00 | -2.65B | 0.00 |
| Purchases of Short-Term Investments | -2.77B | -1.69B | -3.27B | -3.01B |
| Other Cash from Investing Activities | -1.64M | -2.00M | 0.00 | 3.33M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.55B | 377.70M | -2.11B | -856.08M |
| Issuance of Debt | 5.98B | 1.88B | 1.24B | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 476.23M | 166.45M | 86.89M | 49.75M |
| Repayment of Long-Term Debt | -4.71B | -1.35B | 0.00 | 0.00 |
| Repurchase of Capital Stock | -2.04B | -2.22B | -183.12M | -209.46M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 49.32M | -125.62M | 36.12M | 97.84M |
| Net Cash From Financing Activities | -248.73M | -1.65B | 1.18B | -61.87M |
| Effect of Exchange Rate Changes | 14.69M | -23.44M | -2.46M | 17.88M |
| Net Change in Cash & Cash Equivalents | 230.92M | 508.34M | 248.96M | 9.79M |
Portfolios with CELG
- Portfolio NameUser Type
- Userdennis all star
- Userportfolio 1.1
- UserCraigMcIlquham
- User4 Overvalued Biotechs
- ProRay Dalio - Bridgewater Ass...
- ProBill Miller - Legg Mason Ca...
- ContributorStocks Rising On Unusual Vo...
- UserTest Portfolio
- UserMike Fatah's Mega Stock Por...
- User2012 Allocation
Latest CELG Headlines from TheStreet
- Celgene Corporation (CELG): Today's Featured Health Care Winner 05.17.13 | 05:05 pm
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Celgene Stock Hits New 52-Week High (CELG) 05.13.13 | 10:05 am
- Celgene Corporation (CELG): Today's Featured Drugs Winner 05.10.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
- Celgene Corporation (CELG): Today's Featured Drugs Winner 05.03.13 | 05:05 pm
- BMY, CELG And AMGN, 3 Drugs Stocks Pushing The Industry Lower 04.29.13 | 01:04 pm
- 'Mad Money' Lightning Round: Sell Dell ASAP 04.27.13 | 06:04 am
Press Releases for CELG
- Celgene Corporation To Webcast At Two Upcoming Investor Conferences And The American Academy Of Dermatology Annual Meeting - Business Wire 02.28.13 | 08:02 am
- Celgene Announces $600 Million Accelerated Share Repurchase Program - Business Wire 02.20.13 | 08:02 am
- Celgene Provides REVLIMID® Regulatory Update - Business Wire 02.11.13 | 07:02 am
- POMALYST(R) Brand Therapy (Photo: Business Wire) - Business Wire 02.08.13 | 03:02 pm
- Celgene Corporation To Webcast At Upcoming Investor Conferences - Business Wire 02.04.13 | 08:02 am
- Celgene Reports Strong Fourth Quarter And Full Year 2012 Operating And Financial Results - Business Wire 01.24.13 | 07:01 am
- The True Effect: Positive Findings - Research Report On Celgene Corporation And Gilead Sciences, Inc. - PR Newswire 01.23.13 | 08:01 am
- ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer - Business Wire 01.22.13 | 06:01 pm
- Celgene Corporation Announces Financial Outlook And Preliminary 2012 Results - Business Wire 01.07.13 | 11:01 am
- Celgene Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.21.12 | 08:12 am
Partner Headlines for CELG
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks On The Move Table Identifies Emerging Leaders - Investor's Business Daily 04.10.13 | 05:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- Stocks Open Sharply Lower After Employment Report - Investor's Business Daily 04.05.13 | 10:04 am
- Benzinga's Top Upgrades - Benzinga 04.05.13 | 08:04 am
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Top Funds' New Buys: Lumber Liquidators, Celgene - Investor's Business Daily 04.02.13 | 06:04 pm
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
